Founded by Pappas Ventures in 2005, CoLucid is a clinical stage biopharmaceutical company developing therapeutics to treat neurological dysfunctions. CoLucid’s lead asset is lasmiditan, a potent and selective 5-HT1F receptor agonist licensed from Eli Lilly & Co. that has the potential to be useful in the acute treatment of migraine headaches.
CoLucid’s lead asset, lasmiditan, has been shown to be safe and effective in Phase 2b trials.
© 2018 Pappas Capital, LLC. ALL RIGHTS RESERVED.